Literature DB >> 28784323

Polymorphisms in genes related to the complement system and antibody-mediated cardiac allograft rejection.

Grecia M Marrón-Liñares1, Lucía Núñez1, María G Crespo-Leiro2, Eduardo Barge-Caballero2, Jorge Pombo3, María Jesús Paniagua-Martin2, Natalia Suarez-Fuentetaja1, Javier Cid4, Zulaika Grille-Cancela2, Javier Muñiz-Garcia1, Carmela D Tan5, E Rene Rodríguez5, José Manuel Vázquez-Rodríguez2, Manuel Hermida-Prieto6.   

Abstract

BACKGROUND: Heart transplantation (HT) is a life-saving treatment for patients with end-stage heart failure. One of the main problems after HT is the humoral response termed antibody-mediated rejection (AMR). Complement activation plays a key role in AMR contributing to graft damage. The aim of this study was to analyze genetic variants in genes related to the complement pathways that could be associated with the development of AMR.
METHODS: Analysis of 51 genes related to the complement pathway was performed by next-generation sequencing in 46 HT recipients, 23 with and 23 without AMR. Statistical analysis was performed with SNPstats and R.
RESULTS: We identified 2 single nucleotide polymorphisms, 1 in the mannose-binding lectin 2 gene (p.Gly54Asp-MBL2) and 1 in the complement factor properdin gene (p.Asn428(p=)-CFP), that showed significant association with the absence and development of AMR, respectively. Moreover, the presence of the rare allele in p.Gly54Asp-MBL2 control patients correlated with an immunodeficiency of mannose-binding lectin (6.24 ng/ml vs 207.50 ng/ml, p < 0.01), whereas the presence of the rare allele p.Asn428(p=)-CFP in patients with AMR correlated with higher levels of properdin protein (14.65 μg/ml vs 10.77 μg/ml, p < 0.05).
CONCLUSIONS: AMR is a complex phenotype affected by many recipient factors. Variants in p.Gly54Asp-MBL2 and p.Asn428(p=)-CFP genes, encoding mannose-binding lectin 2 and properdin, may influence the risk of AMR.
Copyright © 2018 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antibody-mediated rejection; complement genes; heart transplantation; mannose binding lectin; properdin

Mesh:

Substances:

Year:  2017        PMID: 28784323     DOI: 10.1016/j.healun.2017.07.006

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  5 in total

Review 1.  The innate immune response to allotransplants: mechanisms and therapeutic potentials.

Authors:  Jordi Ochando; Farideh Ordikhani; Peter Boros; Stefan Jordan
Journal:  Cell Mol Immunol       Date:  2019-02-25       Impact factor: 11.530

2.  LIGHT/BTLA polymorphisms and antibody-mediated-rejection after heart transplantation.

Authors:  Grecia M Marrón-Liñares; Lucía Núñez; Manuel Hermida-Prieto
Journal:  Oncotarget       Date:  2018-11-09

Review 3.  Membrane attack complexes, endothelial cell activation, and direct allorecognition.

Authors:  Guiyu Song; Shaoxun Wang; Mahsa Nouri Barkestani; Clancy Mullan; Matthew Fan; Bo Jiang; Quan Jiang; Xue Li; Dan Jane-Wit
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

4.  The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?

Authors:  Marloes A H M Michels; Elena B Volokhina; Nicole C A J van de Kar; Lambertus P W J van den Heuvel
Journal:  Pediatr Nephrol       Date:  2018-08-23       Impact factor: 3.714

5.  Presence of bacterial DNA in thrombotic material of patients with myocardial infarction.

Authors:  P Piñon-Esteban; L Núñez; R Moure; G M Marrón-Liñares; X Flores-Rios; G Aldama-Lopez; J Salgado-Fernandez; R Calviño-Santos; F Rebollal-Leal; R Pan-Lizcano; N Vazquez-Gonzalez; G Bou; M Tomás; M Hermida-Prieto; J M Vazquez-Rodriguez
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.